vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and PATHWARD FINANCIAL, INC. (CASH). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($276.3M vs $180.9M, roughly 1.5× AVANOS MEDICAL, INC.). PATHWARD FINANCIAL, INC. runs the higher net margin — 26.4% vs -0.7%, a 27.1% gap on every dollar of revenue. Over the past eight quarters, PATHWARD FINANCIAL, INC.'s revenue compounded faster (21.0% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
AVNS vs CASH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $276.3M |
| Net Profit | $-1.3M | $72.9M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 26.4% |
| Revenue YoY | 0.7% | — |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $3.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $276.3M | ||
| Q4 25 | $180.9M | $173.1M | ||
| Q3 25 | $177.8M | $186.7M | ||
| Q2 25 | $175.0M | $195.8M | ||
| Q1 25 | $167.5M | $274.8M | ||
| Q4 24 | $179.6M | $182.6M | ||
| Q3 24 | $170.4M | $179.5M | ||
| Q2 24 | $171.7M | $188.6M |
| Q1 26 | — | $72.9M | ||
| Q4 25 | $-1.3M | $35.2M | ||
| Q3 25 | $-1.4M | $38.8M | ||
| Q2 25 | $-76.8M | $42.1M | ||
| Q1 25 | $6.6M | $75.0M | ||
| Q4 24 | $-397.3M | $30.0M | ||
| Q3 24 | $4.3M | $33.5M | ||
| Q2 24 | $1.8M | $44.9M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 24.6% | ||
| Q3 25 | 0.1% | 25.9% | ||
| Q2 25 | -42.6% | 24.1% | ||
| Q1 25 | 6.1% | 33.2% | ||
| Q4 24 | -233.0% | 19.8% | ||
| Q3 24 | 7.0% | 20.9% | ||
| Q2 24 | 3.7% | 27.1% |
| Q1 26 | — | 26.4% | ||
| Q4 25 | -0.7% | 20.3% | ||
| Q3 25 | -0.8% | 20.8% | ||
| Q2 25 | -43.9% | 21.5% | ||
| Q1 25 | 3.9% | 27.3% | ||
| Q4 24 | -221.2% | 16.4% | ||
| Q3 24 | 2.5% | 18.7% | ||
| Q2 24 | 1.0% | 23.8% |
| Q1 26 | — | $3.35 | ||
| Q4 25 | $-0.02 | $1.57 | ||
| Q3 25 | $-0.03 | $1.69 | ||
| Q2 25 | $-1.66 | $1.81 | ||
| Q1 25 | $0.14 | $3.14 | ||
| Q4 24 | $-8.64 | $1.23 | ||
| Q3 24 | $0.09 | $1.34 | ||
| Q2 24 | $0.04 | $1.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $157.6M |
| Total DebtLower is stronger | $90.3M | $59.5M |
| Stockholders' EquityBook value | $778.2M | $850.7M |
| Total Assets | $1.1B | $7.1B |
| Debt / EquityLower = less leverage | 0.12× | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $157.6M | ||
| Q4 25 | $89.8M | $331.2M | ||
| Q3 25 | $70.5M | $120.6M | ||
| Q2 25 | $90.3M | $258.3M | ||
| Q1 25 | $97.0M | $254.2M | ||
| Q4 24 | $107.7M | $597.4M | ||
| Q3 24 | $89.0M | $158.3M | ||
| Q2 24 | $92.2M | $298.9M |
| Q1 26 | — | $59.5M | ||
| Q4 25 | $90.3M | $33.5M | ||
| Q3 25 | $93.4M | $33.5M | ||
| Q2 25 | $95.7M | $33.4M | ||
| Q1 25 | $98.0M | $33.4M | ||
| Q4 24 | $125.3M | $33.4M | ||
| Q3 24 | $152.6M | $33.4M | ||
| Q2 24 | $164.9M | $33.3M |
| Q1 26 | — | $850.7M | ||
| Q4 25 | $778.2M | $854.5M | ||
| Q3 25 | $778.0M | $858.0M | ||
| Q2 25 | $776.3M | $819.0M | ||
| Q1 25 | $839.4M | $814.7M | ||
| Q4 24 | $828.5M | $758.3M | ||
| Q3 24 | $1.2B | $822.5M | ||
| Q2 24 | $1.2B | $748.4M |
| Q1 26 | — | $7.1B | ||
| Q4 25 | $1.1B | $7.6B | ||
| Q3 25 | $1.1B | $7.2B | ||
| Q2 25 | $1.0B | $7.2B | ||
| Q1 25 | $1.1B | $7.0B | ||
| Q4 24 | $1.2B | $7.6B | ||
| Q3 24 | $1.7B | $7.5B | ||
| Q2 24 | $1.7B | $7.5B |
| Q1 26 | — | 0.07× | ||
| Q4 25 | 0.12× | 0.04× | ||
| Q3 25 | 0.12× | 0.04× | ||
| Q2 25 | 0.12× | 0.04× | ||
| Q1 25 | 0.12× | 0.04× | ||
| Q4 24 | 0.15× | 0.04× | ||
| Q3 24 | 0.12× | 0.04× | ||
| Q2 24 | 0.13× | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $108.3M | ||
| Q3 25 | $14.0M | $303.7M | ||
| Q2 25 | $6.8M | $30.4M | ||
| Q1 25 | $25.7M | $188.3M | ||
| Q4 24 | $57.9M | $-71.7M | ||
| Q3 24 | $23.0M | $143.1M | ||
| Q2 24 | $27.8M | $113.2M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $104.1M | ||
| Q3 25 | $7.0M | $300.3M | ||
| Q2 25 | $-4.2M | $27.7M | ||
| Q1 25 | $19.0M | $184.7M | ||
| Q4 24 | $53.1M | $-73.8M | ||
| Q3 24 | $20.0M | $138.8M | ||
| Q2 24 | $21.9M | $111.0M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 60.1% | ||
| Q3 25 | 3.9% | 160.9% | ||
| Q2 25 | -2.4% | 14.1% | ||
| Q1 25 | 11.3% | 67.2% | ||
| Q4 24 | 29.6% | -40.4% | ||
| Q3 24 | 11.7% | 77.3% | ||
| Q2 24 | 12.8% | 58.8% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 2.4% | ||
| Q3 25 | 3.9% | 1.8% | ||
| Q2 25 | 6.3% | 1.4% | ||
| Q1 25 | 4.0% | 1.3% | ||
| Q4 24 | 2.7% | 1.1% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 3.4% | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.08× | ||
| Q3 25 | — | 7.83× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | 3.89× | 2.51× | ||
| Q4 24 | — | -2.39× | ||
| Q3 24 | 5.35× | 4.27× | ||
| Q2 24 | 15.44× | 2.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
